Ceeli Thairianathan: Bridging Biotechnology and Clinical Application
Ceeli Thairianathan, Northeastern Graduate Student, shared a post on LinkedIn:
“Bridging Biotechnology and Clinical Application: Key Insights from Biocytogen
As a biotechnology graduate student, I recently attended a webinar by Biocytogen on the critical role of humanized models in navigating the complexities of cardio-metabolic drug discovery.
Here is a concise technical summary of the platform’s capabilities:
1. Next-Gen Anticoagulation:
Biocytogen is utilizing B-hFXI and B-hFXII plus mice to target the intrinsic coagulation pathway.
This strategy aims to uncouple dangerous thrombosis from essential physiological hemostasis.
2. Precision Cardiomyopathy Models:
The B-Mybpc3 KO model demonstrates high phenotypic fidelity to human disease, exhibiting cardiac enlargement and ventricular wall thickening.
Masson-staining in 17-week-old models provides clear evidence of endocardial collagen fiber proliferation.
3. Systemic Metabolic Solutions:
Advanced multi-target models, such as the B-hLPA/hAPOB/hPCSK9 plus mice, are engineered to evaluate therapies for atherosclerosis and hyperlipidemia.
The broader portfolio addresses NAFLD/MASH, Hyperuricemia, and Diabetic Nephropathy.
4. Integrated Assay Platform:
Beyond the models, Biocytogen provides a robust analytical framework including MSD, FACS, and Luminex to support comprehensive PK/PD/Tox/MoA studies.
These integrated preclinical solutions are essential for accelerating the transition from laboratory research to successful IND filing.
I am grateful for the expert insights shared during this session, which underscored the importance of humanized precision in modern drug discovery.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials